At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
Digoxindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Digoxin as a Novel Inhibitor of Global Hypoxia Inducible Factor-1α (HIF-1α) Expression & Downstream Targets in Breast Cancer: DIG-HIF-1 Pharmacodynamic Trial
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Jan 9, 2013·Updated Jan 31, 2020
In Brief
A Phase 2 clinical trial evaluating Digoxin for Breast Cancer. Completed, enrolled 6 participants across 1 site.
Detailed Summary
The purpose of this study is to learn what effects digoxin (DIG) may have on human breast cancer tissue.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsUnited States Department of Defense
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2013
First PostedJan 2013
Primary CompletionApr 2016
TodayJul 2026
First PostedJan 9, 2013
Enrollment StartJan 1, 2013
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 13.5 years ago
Interventions
Digoxindrug
Digoxin once daily for 2 weeks prior to definitive breast surgery.